Novel tetra-peptide (CAQK) coated nanoparticles to treat Traumatic Brain Injury
A tetra-peptide sequence (CAQK) was identified to treat Traumatic Brain Injury (TBI) a foremost health and socio-economic problem. The CAQK peptide can also be applied to deliver other brain-specific drugs. The peptide, which gathers at the site of damage, could speak to a vital device for TBI finding and focused on treatment. The study was published recently in “Nature Communications”. Intense cerebrum damage, for example, traumatic brain injury (TBI) upsets the ordinary capacity of the cerebrum and for the most part has a poor anticipation for practical recuperation and survival. TBI is a main source of mortality and dismalness in kids, youngsters and adults with ages 1 to 44, with a yearly rate of 2.5 million in the US. TBI can prompt intense and possibly durable neurological brokenness, including the advancement of ceaseless traumatic encephalopathy or Alzheimer’s diseases.
The blood–brain barrier (BBB) is viewed as a noteworthy obstruction to systemic treatment of CNS illnesses. Therefore, restricted conveyance of medications inside the cerebrum has been investigated, yet it has constraints in clinical settings. In intense brain damage and a few cerebrovascular infections, including stroke, hypertension and ischaemia, the BBB is briefly upset, which permits extravascular access for macromolecules and neuroprotective medications from the systemic flow. Actually, the spillage of serum proteins into mind parenchyma is utilized to test for BBB integrity. Be that as it may, absence of particular authoritative of inactively collecting proteins in the harmed region can bring about low maintenance and consequent washout after some time. Because of this leeway, the remedial viability of a systemically regulated medication might be significantly constrained.
The current study investigated on two TBI mouse models, one speaking to penetrating and the other non-penetrating cerebrum damage. They intravenously infuse different peptides into the mouse models for entering brain damage, and limit and individualize CAQK, which is held in the cerebrum at the site of harm by binding to extra cellular matrix (ECM). They then demonstrate that CAQK likewise deposits at the site of harm in mouse models for non-entering cerebrum damage yet does not stockpile in other harmed organs, (for example, skin and liver). The damage stays available to the peptide for in any event up to five days.
The team further finds that the peptide is held through authoritative to a particular protein complex inexhaustibly delivered in TBI in the brains of the mice. The group also extended their discoveries to validate in humans. As a primary approach to inspect CAQK attachment to human brian damage, they tried ex vivo interaction of CAQK-conjugated silver nanoparticles (NP) on human cortical areas got from a head injury tolerant. The CAQK-NPs indicated exceptional binding to the damaged mind segments from the cortex and the corpus callosum zones, while official to typical cerebrum segments was minima. This work opens up the likelihood of nanomedicine-based remedial methodologies for human patients influenced by TBI.
Mann, A. P., Scodeller, P., Hussain, S., Joo, J., Kwon, E., Braun, G. B., Molder, T., She, Z.-G., Kotamraju, V. R., Ranscht, B., Krajewski, S., Teesalu, T., Bhatia, S., Sailor, M. J., and Ruoslahti, E. (2016) A peptide for targeted, systemic delivery of imaging and therapeutic compounds into acute brain injuries. Nat Commun 7